Please ensure Javascript is enabled for purposes of website accessibility

Why Arena Pharmaceuticals' Q2 Results Don't Matter

By Keith Speights – Updated Aug 6, 2020 at 8:35AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

But the company did provide information in its Q2 update that investors should care about.

Arena Pharmaceuticals (ARNA) has made investors happy campers so far in 2020. Its shares are up more than 40%. The company also reported some good news from its pipeline earlier this year and even enjoyed a boost from positive data for a rival's drug.

But when Arena announced its second-quarter results after the market closed on Wednesday, investors basically yawned. Why? The Q2 results really don't matter.

Male scientist in lab mixing formulas.

Image Source: Getty Images.

Essentially meaningless results

Arena reported second-quarter revenue of... zip, nada, nothing. But the average estimate of the 12 analysts surveyed by Refinitiv was for Q2 revenue of $1.47 million. Should that be concerning? Not at all.

The company also posted a net loss in Q2 of $84.9 million, or $1.61 per share, based on generally accepted accounting principles (GAAP). This was somewhat better than Arena's GAAP net loss of $61.4 million, or $1.24 per share, recorded in the prior-year period. It also wasn't nearly as bad as the consensus analysts' estimate of a net loss of $2.03 per share. Again, though, this bottom-line beat isn't anything to get excited about.

Until Arena has a product on the market, any revenue it makes (or doesn't make) simply isn't going to mean much. And how the drugmaker fares relative to analysts' estimates for either the top or bottom line reveals more about how good the analysts are at projecting than it does about how well Arena is performing.

What does matter

There was one financial number in Arena's Q2 update that does matter. The company reported that it had cash, cash equivalents, and marketable securities totaling $1.3 billion as of June 30, 2020. This included nearly $302 million in net proceeds from a stock offering in the second quarter.

This cash stockpile puts Arena in a pretty good position to fund its operations for a while. The company expects to use $400 million to $430 million in cash for operating activities in full-year 2020. Since much of this cash has already been used in the first half of the year, Arena's cash should carry it well into 2021 and perhaps beyond.

But what really matters the most for Arena was its pipeline update, even though much of the information provided wasn't new to investors. The company said that its Advise phase 2b clinical study evaluating etrasimod in treating atopic dermatitis has completed enrollment. It expects to report topline results in the fourth quarter of this year.

Another phase 2b study of the investigational drug in treating Crohn's disease is ongoing. Arena plans to report topline data from the study in 2021, although enrollment could be impacted by the COVID-19 pandemic. The coronavirus outbreak could also affect the company's scheduled start later this year of a phase 2b clinical trial evaluating etrasimod in treating chronic inflammatory disease eosinophilic esophagitis and a phase 2 study of the drug candidate in treating sudden hair-loss disorder alopecia areata.

Perhaps the most important news for the biotech stock in its Q2 update was that the Elevate UC 52 phase 3 study of etrasimod in treating ulcerative colitis remains on track. The company also expects to initiate another phase 3 study of the drug in the indication in the second half of 2020. Arena expects to announce topline results for both studies by the end of next year.

The company stated that the COVID-19 pandemic has caused some issues with enrollment in its Captivate phase 2b study of olorinab in treating abdominal pain associated with irritable bowel syndrome. However, Arena still expects to report initial results in early 2021.

Last, but not least, Arena noted that it has resumed its phase 1 study evaluating APD418 in treating acute heart failure. Topline results are expected in the fourth quarter of 2020.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arena Pharmaceuticals, Inc. Stock Quote
Arena Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.